Early Comparison of Major Bleeding, Stroke and Associated Medical Costs Among Treatment-Naive Non-Valvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban or Warfarin
Amin N Alpesh(University of California, Irvine), Jeffrey Trocio(Pfizer (United States)), Jack Mardekian(Pfizer (United States)), Kevin Odell(Pfizer (United States)), Prianka Singh(Bristol-Myers Squibb (United States)), Onur Başer(STATinMED (United States)), Amanda Bruno(Bristol-Myers Squibb (United States)), Chad Patel, Shalabh Singhal(Integrated BioTherapeutics (United States)), Allison Keshishian(STATinMED (United States)), Lin Xie(STATinMED (United States)), Lien Vo(Bristol-Myers Squibb (United States)), Kwanza Price(Pfizer (United States)), Wilson Tan(Pfizer (United States))
Cited by 3
Related Papers
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase <scp>II</scp>, Randomized, <scp>Double‐Blind</scp>, <scp>Placebo‐Controlled</scp> Trial
|Arthritis & Rheumatology|2022|261
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
|Annals of the Rheumatic Diseases|2022|212
Risk of Major Bleeding with Concomitant Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients Receiving Long‐Term Warfarin Therapy
|Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy|2007|93
Surveillance and Treatment of Non-Muscle-Invasive Bladder Cancer in the USA
|Advances in Urology|2012|36